You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Cytomegalovirus: Are You Up to Speed?

  • Authors: Karen Fowler, DrPH
  • CME / ABIM MOC / CE Released: 7/27/2022
  • Valid for credit through: 7/27/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for obstetrician/gynecologist, pediatricians, primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare providers who care for patients with cytomegalovirus (CMV).

The goal of this activity is that learners will be able to assess their awareness of CMV infection including its burden, risk factors, and clinical impact.

Upon completion of this activity, participants will:

  • Be able to self-assess learning needs related to the
    • Epidemiology of CMV
  • Have increased knowledge related to the
    • Burden of disease of CMV


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Karen Fowler, DrPH

    Professor of Pediatrics
    Division of Infectious Diseases
    Heersink School of Medicine
    University of Alabama at Birmingham
    Birmingham, Alabama


    Karen Fowler, DrPH, has no relevant financial relationships.


  • Iwona Misiuta, PhD, MHA

    Medical Education Director, Medscape, LLC


    Iwona Misiuta, PhD, MHA, has no relevant financial relationships.

  • Gina Montanero, PharmD

    Associate Medical Writer, Medscape, LLC


    Gina Montanero, PharmD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-248-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Cytomegalovirus: Are You Up to Speed?

Authors: Karen Fowler, DrPHFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/27/2022

Valid for credit through: 7/27/2023



  1. Stern L, et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol. 2019;10:1186.
  2. Goodrum F. Human cytomegalovirus latency: approaching the Gordian knot. Annu Rev Virol. 2016;3:333-357.
  3. The American College of Obstetricians and Gynecologists (ACOG). Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. 2015. Accessed June 24, 2022.
  4. Society for Maternal-Fetal Medicine (SMFM), et al. Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol. 2016;214:B5-B11.
  5. Zuhair M, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29:e2034.
  6. Centers for Disease Control and Prevention (CDC). About cytomegalovirus (CMV). 2020. Accessed June 22, 2022.
  7. Adler SP, et al. Cytomegalovirus infections. Pediatr Rev. 2007;28:92-100.
  8. Centers for Disease Control and Prevention (CDC). Babies born with congenital cytomegalovirus (CMV). 2022. Accessed June 22, 2022.
  9. Adler SP. Prevention of maternal-fetal transmission of cytomegalovirus. EBioMedicine. 2015;2:1027-1028.
  10. Boucoiran I, et al. Guideline no. 420: cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2021;43:893-908.
  11. Occupational Safety and Health Administration (OSHA). Cytomegalovirus. Accessed June 22, 2022.
  12. Centers for Disease Control and Prevention (CDC). Cytomegalovirus (CMV) and congenital CMV infection: laboratory testing. 2020. Accessed June 22, 2022.
  13. Chung MH, et al. TORCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) screening of small for gestational age and intrauterine growth restricted neonates: efficacy study in a single institute in Korea. Korean J Pediatr. 2018;61:114-120.
  14. van der Weiden S, et al. Is routine TORCH screening and urine CMV culture warranted in small for gestational age neonates? Early Hum Dev. 2011;87:103-107.
  15. Gantt S, et al. Diagnosis and management of infants with congenital cytomegalovirus infection. Paediatr Child Health. 2017;22:72-74.
  16. Rawlinson WD, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17:e177-e188.
  17. Gantt S, et al. Performance of the Alethia CMV assay for detection of cytomegalovirus by use of neonatal saliva swabs. J Clin Microbiol. 2020;58:e01951-e01919.
  18. Manicklal S, et al. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26:86-102.
  19. Chatzakis C, et al. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol. 2020;223:870-883.e11.
  20. Vauloup-Fellous C, et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol. 2009;46(Suppl 4):S49-S53.
  21. Cannon MJ, et al. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health. 2005;5:70.
  22. Revello MG, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014;370:1316-1326.
  23. Doutre SM, et al. Losing ground: awareness of congenital cytomegalovirus in the United States. J Early Hear Detect Interv. 2016;1:39-48.
  24. Centers for Disease Control and Prevention (CDC). Congenital CMV and hearing loss. 2020. Accessed June 23, 2022.
  25. Luck SE, et al. Congenital cytomegalovirus. Pediatric Infect Dis J. 2017;36:1205-1213.
  26. Scarpini S, et al. Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice. Vaccines (Basel). 2021;9:551.
  27. Midgley G, et al. Congenital cytomegalovirus prevention, awareness and policy recommendations - a scoping study. Infect Disord Drug Targets. 2020;20:291-302.
  28. A study to evaluate the efficacy, safety, and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in healthy participants 16 to 40 years of age. Accessed June 23, 2022.
« Return to: Cytomegalovirus: Are You Up to Speed?
  • Print